Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 PK, safety and tolerability of SAR443765 in healthy Japanese adults
jRCT2071220112Phase 1Completed
- Sponsor
- Sanofi
- Start
- Mar 2023
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lunsekimig (2 arms), sponsored by Sanofi. Primary endpoints: Cmax, AUClast and 1 more. Started Mar 2023; status: completed.
02
Drugs
lunsekimig
Beyond the preview
Go deeper on jRCT2071220112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071220112.